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flow measurement of the carotid artery, myocardial and cerebral perfusion using
fluorescent microspheres were performed during baseline (M1), sheath forwarding
(M2), stent-graft deployment (M3) and after retraction of the sheath (M4) for
evaluation of hemodynamic changes during transseptal deployment and concomitant
myocardial and cerebral perfusion deficiency.
Results: Stent graft deployment into the ascending aorta was feasible in all six animals.
Coronary arteries were patent in all cases confirmed by fluoroscopy. In four animals
(66%) the innominate artery was partially occluded reflected by reduced carotid blood-
flow. During advancing of the stent-graft transient hemodynamic instability due to
severe mitral valve insufficiency occurred in all animals (M2, M3), after retrieval of
the delivery-system (M4) hemodynamic stability recovered within ten minutes in all
animals.
Conclusion: Transseptal access to the ascending aorta in a porcine model is feasible.
Transient hemodynamic instability recovered to near preoperative values. Assessment
of cerebral and myocardial perfusion for evaluation of the severity of the periprocedural
deterioration using fluoresecent microspheres is under evaluation. Antegrade
transseptal stentgraft deployment might be a promising tool.
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Background: In-stent stenosis, the principal cause PCI failure, is associated with
reduced endothelial nitric oxide (NO) bioavailability. Tetrahydrobiopterin (BH4) is a
required cofactor for NO synthesis by endothelial nitric oxide synthase (eNOS).
Methods: We investigated the importance of BH4 in regulating eNOS activity in in-
stent stenosis using a transgenic mouse with endothelial overexpression of the
rate-limiting enzyme in BH4 synthesis, GTP-cyclohydrolase I (GCH). Thoracic aortic
segments which underwent balloon angioplasty and stenting from donor transgenic
mice crossed onto ApoE-KO background (GCH-Tg/ApoE-KO) or their ApoE-KO
littermates were grafted onto the carotid artery of isogenic recipients.
Results: Aortic BH4 levels were 8-fold higher in GCH-Tg/ApoE-KO mice compared
to ApoE-KO controls (P<0.01). Despite equal stent expansion and injury scores, in-
stent stenosis was reduced by 47% (P<0.001) in GCH-Tg/ApoE-KO mice. NO
synthesis, measured using arginine to citrulline conversion and electron paramagnetic
resonance in aorta of experimental animals, was not different between groups.
However, O2- production was significantly attenuated in GCH-Tg/ApoE-KO mice
measured on both aortic sections using oxidative confocal microtopography and whole
aorta by lucigenin enhanced chemiluminescence. eNOS inhibition by L-NAME
reversed these effects indicating that under basal conditions GCH-Tg/ApoE-KO mice
had preserved eNOS coupling promoting NO synthesis.
Conclusion: These results indicate that a reduction in-stent stenosis is conferred by
maintaining eNOS coupling and reducing O2- production. These findings highlight
the importance of eNOS function in in-stent stenosis.
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Background: In clinical practice, myocardial necrosis (MN) is determined by Troponin
(Trop) which can be detected only several hours after onset of ischemia. In search for
early specific and accurate biomarkers to determine MN and quantify infarct size (IS),
we evaluated heart specific fatty acid binding protein (hFABP), a small cytosolic,
cardiac specific marker released during acute myocardial infarction (AMI) ±
reperfusion (R) in comparison to Trop and morphometric triphenyl tetrazolium chloride
infarct size determination (TTC).
Methods: In 8 swine, AMI was induced by 8 hr chronic balloon occlusion (C) or 2 hr
balloon occlusion followed by 6 hr reperfusion (R). Blood samples were taken at
predetermined intervals and analyzed for hFABP and high sensitivity Troponin I (Trop
I). TTC was used to determine IS.
Results: In AMI-C hFABP was detected faster than Trop upon occlusion (90±35 vs.
188±62 min, mean ± SD, p<0.04) with peak values at 5±1 hr. Trop I did not reach peak
levels in 8 hr. Area under Curve (AUC) for hFABP and Trop I did not correlate strongly
with IS (R2 =0.57 vs. 0.34). In AMI-R (Fig.), hFABP increased immediately upon
reperfusion while Trop I was delayed 20±15 min. (p=0.03). hFABP peak values were
reached in 38±15 min after R, Trop. I in 145±15min. (p<0.001). IS by TTC correlated
well with 8 hr AUC both for both markers (R2=0.90). However, hFABP reperfusion
peak values (Fig.) showed the highest correlation (R2=0.98 vs. 0.87). Moreover the
intercept value of the trendline nearly coincides with mean baseline hFABP values.
Conclusion: H-FABP release rises significantly faster and correlates better with IS
than Trop I in a large animal ischemia-reperfusion model. Maximal hFABP release can
be measured within 1 hr upon reperfusion or 5 hr in chronic MI. Taken together, hFABP
is an accurate and very fast biomarker for longitudinal in vivo measurement of infarct
size in a swine.
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Background: Acute myocardial infarction (AMI) and heart failure remain the leading
cause of death in United States. Availability of a reproducible large animal model with
a large infarction and ejection fraction below 35% is highly desirable for the evaluation
of novel myocardial regenerative therapies including cell therapy, injectable matrices,
cardiac resynchronization therapy (CRT), and CRT-drug combinations. The goal was
to develop a reproducible swine model of myocardial infarction and heart failure with
average ejection fraction (EF) below 35%.
Methods: A total of 18 Yucatan miniature pigs underwent minimally invasive closed-
chest induction of AMI by percutaneous infusion of collagen gel into the left anterior
descending coronary artery (LAD) and side branches under fluoroscopic guidance.
Complete occlusion of the LAD and side branches was confirmed and maintained over
2hrs as assessed by coronary angiography. After 3 months, cardiac function was
evaluated in surviving pigs (12 of 18) and one naïve uninfarcted Yucatan pig as control
using a 1.5T MRI System (MR143 Siemens Magnetom Avanto). Analysis was
performed using Circle Cardiovascular Imaging’s CMR42 software. Left ventricular
volumes at end systole (LVESD) and diastole (LVEDD), ejection fraction (EF), and
wall thickness (WT) in the area at risk (AAR) and normal zone (NZ) were calculated.
Results: LVESV and LVEDV in the infarcted pigs were 4- and 2-fold higher,
respectively, compared to control. EF was reduced in infarcted pigs compared to control
(27.0± 2.3 vs. 59.9%, respectively). WT in AAR and NZ were reduced by 6- and 2-
fold, respectively, in infarcted pigs compared to control.
Conclusion: We have shown that percutaneous infusion of collagen gel into the porcine
coronary circulation generates large myocardial infarctions associated with severe
cardiac dysfunction and EF below 35%. This highly reproducible model is an important
tool for testing of therapies for AMI and congestive heart failure.
B123JACC Vol 58/20/Suppl B  |  November 7-11, 2011  |  TCT Abstracts/POSTER/Basic Science, Animal Models and Preclinical Studies
P
O
S
T
E
R
S
www.JACC.TCTAbstracts2011
